The use of single chain Fv as targeting agents for immunoliposomes: An update on immunoliposomal drugs for cancer treatment

Expert Opinion on Drug Delivery

Volumn 7, Issue 4, 2010, Pages 461-478

  Cheng, W W ^b,c   Allen, T M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Biodistribution; Cancer; Drug delivery; Fab ; Immunoliposomes; Liposomes; Monoclonal antibodies; Pharmacokinetics; ScFv

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CARCINOEMBRYONIC ANTIBODY; CD19 ANTIBODY; CD19 ANTIGEN; CD22 ANTIBODY; CD45 ANTIBODY; CIPROFLOXACIN; CYSTEINE; CYTARABINE; DAUNORUBICIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; FLUIDOSOME TOBRAMYCIN; FOLATE BINDING PROTEIN; HYDRAZIDE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL; MALEIMIDE; MARQIBO; MESOTHELIN ANTIBODY; MONOCLONAL ANTIBODY; NITRILOTRIACETATE NICKEL; OKT 3; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOBRAMYCIN; TOPOTECAN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER MODEL; DISULFIDE BOND; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TARGETING; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOGENICITY; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; MELANOMA; MENINGITIS; METASTASIS; MYCOSIS; NEOPLASM; NONHUMAN; OVARY CANCER; PSEUDOMONAS INFECTION; REVIEW; VISCERAL LEISHMANIASIS;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LIPOSOMES; SINGLE-CHAIN ANTIBODIES;

EID: 77949900348     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903579963     Document Type: Review

References (165)

1. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-252
2. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-1822
3. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994;14(Suppl 5):S3-7
4. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-1454
5. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of
6. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993;341(8855):1242-1243
7. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-3402
8. Zhigaltsev IV, Maurer N, Akhong QF, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 2005;104(1):103-111
9. Sachetelli S, Beaulac C, Riffon R, Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta 1999;1428(2-3):334-340
10. Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305(1-2):180-185
11. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63(21):7400-7409
12. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233:134-144
13. Suzuki S, Inoue K, Hongoh A, et al. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J Cancer 1997;76(1):83-89
14. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986;46(12 Pt 1):6387-6392
15. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61(7):3027-3032
16. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-284
17. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2(4):369-381
18. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2(10):750-763
19. Park JW, Benz CC, Martin FJ. Future directions of liposome-and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31(6 Suppl 13):196-205
20. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006;8(1):39-45
21. Romberg B, Metselaar JM, Baranyi L, et al. Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. Int J Pharm 2007;331(2):186-189
22. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88(24):11460-11464
23. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-992
24. Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006;6(6):513-523
25. Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663(1-2):167-177
26. Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567-3573
27. Johnston MJ, Semple SC, Klimuk SK, et al. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 2006;1758(1):55-64
28. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62(24):7190-7194
29. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66(13):6732-6740
30. Roth A, Drummond DC, Conrad F, et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007;6(10):2737-2746
31. Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66(20):10073-10082
32. Pastorino F, Di Paolo D, Piccardi F, et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008;14(22):7320-7329
33. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-1181
34. Roth P, Hammer C, Piguet AC, et al. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target 2007;15(9):623-631
35. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004;10(7):2530-2537
36. Atobe K, Ishida T, Ishida E, et al. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 2007;30(5):972-978
37. Li SD, Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann NY Acad Sci 2006;1082:1-8
38. Chen H, Ahn R, Van den Bossche J, et al. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009;8(7):1955-1963
39. Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 2008;346(1-2):143-150
40. Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002;17(6):621-630
41. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24(13):2121-2143
42. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5(Suppl 1):S37-47
43. Daeron M, Prouvost-Danon A, Voisin GA. Mast cell membrane antigens and Fc receptors in anaphylaxis. II. Functionally distinct receptors for IgG and for IgE on mouse mast cells. Cell Immunol 1980;49(1):178-189
44. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60-70
45. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003;8(11):503-510
46. Thorpe SJ, Turner C, Heath A, et al. Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol 2003;57(1):85-92
47. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147-1157
48. Qu Z, Griffiths GL, Wegener WA, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005;36(1):84-95
49. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81(21):6851-6855
50. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity- determining regions in a human antibody with those from a mouse. Nature 1986;321(6069):522-525
51. Baskar S, Suschak JM, Samija I, et al. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood 2009;114(20):4494-4502
52. Bartelds GM, Wolbink GJ, Stapel S, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006;65(9):1249-1250
53. de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66(9):1252-1254
54. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 2009 [Epub ahead of print]
55. Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 2008;126(1):50-58
56. Kipriyanov SM, Moldenhauer G, Little M. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J Immunol Methods 1997; 200(1-2):69-77
57. Houdebine LM. Antibody manufacture in transgenic animals and comparisons with other systems. Curr Opin Biotechnol 2002;13(6):625-629
58. Pini A, Bracci L. Phage display of antibody fragments. Curr Protein Pept Sci 2000;1(2):155-169
59. Lindner P, Bauer K, Krebber A, et al. Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Biotechniques 1997;22(1):140-149
60. Pavlinkova G, Colcher D, Booth BJ, et al. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int J Cancer 2001;94:717-726
61. Roque-Navarro L, Mateo C, Lombardero J, et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003;22(4):245-257
62. Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B-lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res 2004;10(3):1100-1111
63. Zalipsky S. Synthesis of end-group functionalized polyethylene glycol-lipid conjugates for preparation of polymer-grafted liposomes. Bioconjugate Chem 1993;4:296-299
64. Allen TM, Brandeis E, Hansen CB, et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237:99-108
65. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75
66. Bendas G, Krause A, Bakowsky U, et al. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharmaceutics 1999;181(1):79-93
67. Torchilin VP, Levchenko TS, Lukyanov AN, et al. p-Nitrophenylcarbonyl- PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 2001;1511:397-411
68. Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res 2003;63(12):3154-3161
69. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63(1):86-92
70. Marty C, Langer-Machova Z, Sigrist S, et al. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett 2006;235(2):298-308
71. Cheng WW, Das D, Suresh M, Allen TM. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta 2007;1768(1):21-29
72. Messerschmidt SK, Kolbe A, Muller D, et al. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug Chem 2008;19(1):362-369
73. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58(15):3320-3330
74. Hansen CB, Kao GY, Moase EH, et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995;1239:133-144
75. Pan X, Lee RJ. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int J Pharm 2007;336(2):276-283
76. Ruger R, Muller D, Fahr A, Kontermann RE. Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J Drug Target 2005;13(7):399-406
77. Ruger R, Muller D, Fahr A, Kontermann RE. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J Drug Target 2006;14(8):576-582
78. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999;460(1):129-133
79. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim Biophys Acta 2001;1513(2):207-216
80. Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed Stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 2002;19(3):265-269
81. Nellis DF, Ekstrom DL, Kirpotin DB, et al. Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting conjugate. 1. Gram-Scale Production and Purification. Biotechnol Prog 2005;21(1):205-220
82. Nellis DF, Giardina SL, Janini GM, et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 2005;21(1):221-232
83. Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000;1466(1-2):205-220
84. Zalipsky S, Hansen CB, Lopes de Menezes DE, Allen TM. Long-circulating polyethylene glycol-grafted immunoliposomes. J Control Release 1996;39:153-161
85. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65(24):11631-11638
86. Noble CO, Guo Z, Hayes ME, et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009;64(4):741-751
87. Bendas G, Rothe U, Scherphof GL, Kamps JA. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim Biophys Acta 2003;1609(1):63-70
88. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008;354(1-2):56-62
89. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007;119(2):236-244
90. Goren D, Horowitz AT, Zalipsky S, et al. Targeting of Stealth liposomes to erB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996;74:1749-1756
91. Houck KS, Huang L. The role of multivalency in antibody mediated liposome targeting. Biochem Biophys Res Commun 1987;145(3):1205-1210
92. Maruyama K, Takahashi N, Tagawa T, et al. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997;413(1):177-180
93. Baum P, Muller D, Ruger R, Kontermann RE. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target 2007;15(6):399-406
94. An F, Drummond DC, Wilson S, et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 2008;7(3):569-578
95. Messerschmidt SK, Musyanovych A, Altvater M, et al. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 2009;137(1):69-77
96. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59(22):5758-5767
97. Worn A, Auf der Maur A, Escher D, et al. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem 2000;275(4):2795-2803
98. Pedroso I, Irun MP, Machicado C, Sancho J. Four-state equilibrium unfolding of an scFv antibody fragment. Biochemistry 2002;41(31):9873-9884
99. Brockmann EC, Cooper M, Stromsten N, et al. Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J Immunol Methods 2005;296(1-2):159-170
100. Shusta EV, Holler PD, Kieke MC, et al. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 2000;18(7):754-759
101. Kipriyanov SM, Moldenhauer G, Martin AC, et al. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997;10(4):445-453
102. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001;305(5):989-1010
103. Worn A, Pluckthun A. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 1999;38(27):8739-8750
104. Arndt MA, Krauss J, Rybak SM. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 2004;578(3):257-261
105. Cheng WW. Targeted delivery of immunoliposomal doxorubicin to B-lymphoid cells via an anti-CD19 whole monoclonal antibody or fragments of antibody. Edmonton: University of Alberta; 2008
106. Proba K, Honegger A, Pluckthun A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol 1997;265(2):161-172
107. Glockshuber R, Schmidt T, Pluckthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 1992;31(5):1270-1279
108. Proba K, Worn A, Honegger A, Pluckthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 1998;275(2):245-253
109. Worn A, Pluckthun A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 1998;427(3):357-361
110. de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact 2009;8:26-43
111. Reiter Y, Brinkmann U, Webber KO, et al. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng 1994;7(5):697-704
112. Reiter Y, Brinkmann U, Jung SH, et al. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. Protein Eng 1995;8(12):1323-1331
113. Robinson CR, Sauer RT. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci USA 1998;95(11):5929-5934
114. Villani ME, Morea V, Consalvi V, et al. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting. Mol Immunol 2008;45(9):2474-2485
115. Quintero-Hernandez V, Juarez-Gonzalez VR, Ortiz-Leon M, et al. The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol 2007;44(6):1307-1315
116. Juarez-Gonzalez VR, Riano-Umbarila L, Quintero-Hernandez V, et al. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J Mol Biol 2005;346(5):1287-1297
117. Dona MG, Giorgi C, Accardi L. Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis. BMC Cancer 2007;7:25-38
118. Kugler M, Stein C, Schwenkert M, et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 2009;22(3):135-147
119. Guisez Y, Demolder J, Mertens N, et al. High-level expression, purification, and renaturation of recombinant murine interleukin-2 from Escherichia coli. Protein Expr Purif 1993;4(3):240-246
120. Seddon AP, Hulmes JD, Decker MM, et al. Refolding and characterization of human recombinant heparin-binding neurite-promoting factor. Protein Expr Purif 1994;5(1):14-21
121. Hoyer M. RK, Pluckthun A. A kinetic trap is an intrinsic feature in the folding pathway of single-chain Fv fragments. Biophys Chem 2002;96(2-3):273-284
122. Francis RJ, Mather SJ, Chester K, et al. Radiolabelling of glycosylated MFE-23: CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). Eur J Nucl Med Mol Imaging 2004;31(8):1090-1096
123. Lin Y, Pagel JM, Axworthy D, et al. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66(7):3884-3892
124. Goel A, Beresford GW, Colcher D, et al. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. J Biochem 2000;127(5):829-836
125. Wittel UA, Jain M, Goel A, et al. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32(2):157-164
126. Das D, Allen TM, Suresh MR. Comparative evaluation of two purification methods of anti-CD19-c-myc-His(6)-Cys scFv. Protein Expr Purif 2005;39(2):199-208
127. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23(9):1137-1146
128. Mayer A, Francis RJ, Sharma SK, et al. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 2006;12(21):6509-6516
129. Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11(4):1545-1550
130. Filpula D, Yang K, Basu A, et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem 2007;18(3):773-784
131. Laane E, Tani E, Bjorklund E, et al. Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. Cytometry B Clin Cytom 2005;64(1):34-42
132. Laginha K, Mumbengegwi D, Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005;1711(1):25-32
133. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl 2):2-9
134. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22(47):7359-73568
135. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102(10):3514-3520
136. Wobser M, Voigt H, Eggert AO, et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 2007;96(10):1540-1543
137. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002;99(6):783-791
138. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65(2):473-482
139. Moase EA, Allen TM. Combination targeting of immunoliposomal therapeutics in a murine model of B-Cell lymphoma. 36th Annual Meeting & Exposition of the Controlled Release Society. Copenhagen, Denmark; 2009
140. Hare JIM, Moase EA, Allen TM. Combined Anti-vasculature and Anti-tumor Targeting in the Treatment of Metastatic Breast Cancer. 36th Annual Meeting & Exposition of the Controlled Release Society. Copenhagen, Denmark; 2009
141. Abraham SA, McKenzie C, Masin D, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004;10(2):728-738
142. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5(7):1854-1863
143. Tardi PG, Gallagher RC, Johnstone S, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 2007;1768(3):678-687
144. Caplen NJ, Kinrade E, Sorgi F, et al. In vitro liposome mediated DNA transfection of epithelial cell lines using the cationic liposome Dc Chol/Dope. Gene Ther 1995;2(9):603-613
145. de Lima MC, Simoes S, Pires P, et al. Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mol Membr Biol 1999;16(1):103-109
146. Ishida T, Kirchmeier MJ, Moase EH, et al. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 2001;1515:144-158
147. Kakudo T, Chaki S, Futaki S, et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004;43(19):5618-5628
148. Kirpotin D, Hong K, Mullah N, et al. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 1996;388:115-118
149. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001;98(15):8786-8791
150. Zhang JX, Zalipsky S, Mullah N, et al. Pharmaco attributes of dioleoylphosphatidylethanolamine/ cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol Res 2004;49:185-198
151. Boomer JA, Qualls MM, Inerowicz HD, et al. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug Chem 2009;20(1):47-59
152. Cao Y, Suresh MR. Bispecific mAb aided liposomal drug delivery. J Drug Target 2000;8(4):257-266
153. Bruenke J, Fischer B, Barbin K, et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 2004;125(2):167-179
154. Kellner C, Bruenke J, Stieglmaier J, et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008;31(9):871-884
155. Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33(9):1233-1242
156. Horn U, Strittmatter W, Krebber A, et al. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol 1996;46(5-6):524-532
157. Hu S, Li L, Qiao J, et al. Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris. Protein Expr Purif 2006;47(1):249-257
158. Kumada Y, Sakan Y, Kajihara H, et al. Efficient production of single-chain Fv antibody possessing rare codon linkers in fed-batch fermentation. J Biosci Bioeng 2009;107(1):73-77
159. Hu X, O'Hara L, White S, et al. Optimisation of production of a domoic acid-binding scFv antibody fragment in Escherichia coli using molecular chaperones and functional immobilisation on a mesoporous silicate support. Protein Expr Purif 2007;52(1):194-201
160. Shaki-Loewenstein S, Zfania R, Hyland S, et al. A universal strategy for stable intracellular antibodies. J Immunol Methods 2005;303(1-2):19-39
161. Jurado P, de Lorenzo V, Fernandez LA. Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin. J Mol Biol 2006;357(1):49-61
162. Sonoda H, Kumada Y, Katsuda T, Yamaji H. Functional expression of single-chain Fv antibody in the cytoplasm of Escherichia coli by thioredoxin fusion and co-expression of molecular chaperones. Protein Expr Purif 2009 [Epub ahead of print]
163. Wall JG, Pluckthun A. The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli. Protein Eng 1999;12(7):605-611
164. Franklin SE, Mayfield SP. Prospects for molecular farming in the green alga Chlamydomonas. Curr Opin Plant Biol 2004;7(2):159-165
165. Zhang G, Brokx S, Weiner JH. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nat Biotechnol 2006;24(1):100-104